Results 71 to 80 of about 939 (187)
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2020 A growing body of evidence has implicated the calcitonin gene-related peptide (CGRP) receptors in migraine pathophysiology. With the recent approval of monoclonal antibodies targeting CGRP or the CGRP receptor, the inhibition of CGRP-mediated signaling has emerged as a promising approach for preventive treatments of migraine in adults.
Eric, Moore +11 more
openaire +2 more sources
Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 2138-2155, October 2026.Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland +7 more
wiley +1 more source
Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment
MedComm, Volume 7, Issue 9, September 2026.Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu +9 more
wiley +1 more source
Pharmaceutics, 2020 In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on ...
Danuta Szkutnik-Fiedler
doaj +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 6, June 2026.Abstract A population pharmacokinetic (popPK) model was developed for ubrogepant using data from 10 Phase 1, 1 Phase 2, and 2 Phase 3 studies. The data were described by a 2‐compartment model with linear elimination and transit compartment absorption. Formulation, food intake, race, gender, and hepatic impairment had a statistically significant impact ...
Sven Stodtmann +3 more
wiley +1 more source
Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik +44 more
wiley +1 more source
Therapeutic novelties in migraine: new drugs, new hope?
The Journal of Headache and Pain, 2019 Background In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.
Thien Phu Do, Song Guo, Messoud Ashina
doaj +1 more source
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants (N = 28) were enrolled into this phase 1, open‐label study and received atogepant 60 mg once daily for 8 days. Steady‐state atogepant concentrations were determined from CSF samples collected on Day 6 at 2
Ramesh R. Boinpally, Joel M. Trugman
wiley +1 more source
The role of SARS-COV-2 -Main Protease: the case of Gepants family and Veruprevir [PDF]
, 2023 In this study, our approach was to conduct a complete investigation of molecular docking analysis with the major SARS-CoV-2 proteins and SARS CoV-1 proteins. We analyzed more than 6000 drugs, downloaded by the Pubchem database.
Rocca, Blasco Morozzo della +3 more
core
Drug, Healthcare and Patient Safety, 2021 Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology ...
Lo Castro F, Guerzoni S, Pellesi L
doaj